ClinicalTrials.gg
CompletedNCT01512979Updated May 20, 2014Results posted

Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes

A Phase 4 interventional study of metformin and linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 82 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
19th of 67
316 · median 175
Started
2012
with 5 others
Phase 4
22 of 67
1 open now
Registered
27th of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment, is one of 6 that started in 2012, is one of 22 in phase 4, and was the 27th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must sign and date an consistent with International Conference on Harmonisation / Good Clinical Practice guidelines and local regulations prior to any evaluation and participation in the trial.
  2. Male and female patients, 18 years of age or older at Visit 1 (Screen), with newly diagnosed (less than 12 months prior to Screen) Type 2 Diabetes Mellitus.
  3. Patients who are treatment-naïve, defined as absence of any oral antidiabetic therapy, injectable glucagon-like peptide-1 agonist/analogue, or insulin, and uncontrolled for the 12 weeks prior to randomisation.
  4. Patients must have an glycated (or glycosylated) () between 8.5% [69 millimoles per mole (mmol/mol)] and 12.0% (108 mmol/mol) at Visit 1 (Screen).
  5. Patients must have a (BMI) of 45 kg/m2 or less at Visit 1 (Screen).
  6. In the investigators opinion, patients must be reliable, honest, compliant, and agree to cooperate with all planned future trial evaluations as explained in detail during the informed consent process and to be able to perform them.

Exclusion criteria

Exclusion criteria:

Patients with, who are, who have, or who have had:

  1. Acute coronary syndrome (non-ST Elevation Myocardial Infarction (STEMI), STEMI, and unstable angina pectoris), stroke or within 3 months prior to .
  2. Indication of liver disease determined during Screen and/or Run-In Period, defined by a serum level above 3 times the (ULN) in any of the following: , aspartate aminotransferase, or alkaline phosphatase. Gilbert-Meulengracht syndrome (also known as conjugated hyperbilirubinemia, constitutional hepatic dysfunction, or familial nonhemolytic jaundice) will be permitted.
  3. Impaired renal function, defined as calculated of less than 60 milliliters per minute (\< 60 mL/min), by the Cockcroft-Gault Equation, as determined during Screen and/or Run-In Period.
  4. Bariatric, gastric bypass, and other gastrointestinal surgeries (including all types of gastric banding and/or LapBand) within the past two years.
  5. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years.
  6. Medical history of pancreatitis.
  7. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., malaria, babesiosis, haemolytic anaemia).
  8. Any to metformin and/or linagliptin therapies, according to local labels.
  9. Treatment with anti-obesity drugs, including over-the-counter drugs such as Alli (orlistat), 3 months prior to informed consent or any other treatment at the time of screening (i.e., surgery, aggressive diet regimen, etc.) leading to unstable body weight.
  10. Current treatment with systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes Mellitus.
  11. Pre-menopausal women (last menstruation of 1 year or less prior to informed consent) who are nursing or pregnant, are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the trial and do not agree to submit to periodic pregnancy testing during participation in the trial.

    Note: Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable, intra-vaginal, or injectable contraceptives, Essure micro-inserts placed more than six months prior to Screen Visit, complete sexual abstinence (if acceptable by local authorities), double barrier method (e.g., diaphragm or condom and spermicide), and vasectomised partner.

  12. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance to trial procedures or study medication intake in the opinion of the investigator.
  13. Participation in another trial with an drug within 2 months prior to informed consent.
  14. Any other clinical condition that would jeopardize patient safety while participating in this clinical trial in the opinion of the Investigator.
  15. Inability to commit to regular overnight fasting of at least 10 hours duration and attendance to study site visits between 07:00 and 11:00 ante meridiem (a.m.).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
316 participants (actual)

Study arms

  • Experimental
    linagliptin

    patients receive linagliptin tablet once daily

    Drug: linagliptin · Drug: metformin placebo

  • Experimental
    linagliptin plus metformin

    patients receive linagliptin tablet once daily and metformin tablets twice daily

    Drug: metformin · Drug: linagliptin · Drug: metformin placebo

Interventions

  • 1000 mg to 2000 mg per day

  • 5 mg daily

  • Drugmetformin placebo

    0 to 2 tablets daily

  • Drugmetformin placebo

    4 tablets daily

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c After 24 Weeks

    HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment

    The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.

    Time frame: Baseline and 24 weeks

  2. Change From Baseline in HbA1c by Visit Over Time

    HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.

    Time frame: Baseline, 6, 12, 18 and 24 weeks

  3. Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)

    The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.

    Time frame: Baseline and 24 weeks

  4. Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)

    The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.

    Time frame: Baseline and 24 weeks

  5. Occurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment

    The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.

    Time frame: Baseline and 24 weeks

  6. Change From Baseline in FPG by Visit Over Time

    The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.

    Time frame: Baseline, 6, 12, 18 and 24 weeks

07

Results

Posted May 9, 2014

Participant flow

Participant flow — Overall Study
MilestoneLinagliptin 5mg + MetforminLinagliptin 5mg
Started159157
Completed140135
Not completed1922
Withdrew: Adverse event22
Withdrew: Protocol violation14
Withdrew: Lost to follow-up25
Withdrew: Withdrawal by subject12
Withdrew: Reason other than stated above139

Outcome measures

PrimaryChange From Baseline in HbA1c After 24 Weeks

HbA1c is measured as a percentage. The change from baseline is the Week 24 HbA1c minus the baseline HbA1c. Means are adjusted for treatment and continuous baseline HbA1c

Time frame:
Baseline and 24 weeks
Reported as:
Mean · percent
Change From Baseline in HbA1c After 24 Weeks
percentLinagliptin 5mg + MetforminLinagliptin 5mg
Change From Baseline in HbA1c After 24 Weeks-2.81 ± 0.12-2.02 ± 0.13
Statistical analysis
  • Linagliptin 5mg + Metformin vs Linagliptin 5mg · ANCOVA · p = <0.0001 (The model includes treatment and continuous baseline HbA1c.) · Mean difference (final values): -0.79 · 95% CI -1.13 to -0.46
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment

The change from baseline is the FPG after 24 weeks minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c and continuous baseline fasting plasma glucose.

Time frame:
Baseline and 24 weeks
Reported as:
Mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment
mg/dLLinagliptin 5mg + MetforminLinagliptin 5mg
Change From Baseline in Fasting Plasma Glucose (FPG) After 24 Weeks of Treatment-47.1 ± 3.8-30.2 ± 4.2
Statistical analysis
  • Linagliptin 5mg + Metformin vs Linagliptin 5mg · ANCOVA · p = 0.0032 (The model includes treatment, continuous baseline HbA1c and continuous baseline FPG.) · Mean difference (final values): -16.9 · 95% CI -28.0 to -5.7
SecondaryChange From Baseline in HbA1c by Visit Over Time

HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes treatment, continuous baseline HbA1c in addition to week repeated within patient, week by baseline HbA1c interaction and week by treatment interaction.

Time frame:
Baseline, 6, 12, 18 and 24 weeks
Reported as:
Mean · percent
Change From Baseline in HbA1c by Visit Over Time
percentLinagliptin 5mg + MetforminLinagliptin 5mg
Change to week 6-1.97 ± 0.09-1.33 ± 0.10
Change to week 12-2.69 ± 0.11-1.85 ± 0.12
Change to week 18-2.79 ± 0.11-2.01 ± 0.12
Change to week 24-2.81 ± 0.12-2.01 ± 0.13
SecondaryOccurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)

The proportion of patients who achieved HbA1c lowering by at least 0.5% after 24 weeks of treatment.The model includes treatment, and continuous baseline HbA1c.

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)
participantsLinagliptin 5mg + MetforminLinagliptin 5mg
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 24 Weeks of Treatment)12492
Statistical analysis
  • Linagliptin 5mg + Metformin vs Linagliptin 5mg · Regression, Logistic · p = 0.0031 (The model includes treatment and continuous baseline HbA1c.) · Odds ratio (or): 3.830 · 95% CI 1.573 to 9.328
SecondaryOccurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)

The proportion of patients who achieved HbA1c lowering by at least 1.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)
participantsLinagliptin 5mg + MetforminLinagliptin 5mg
Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 1.0% After 24 Weeks of Treatment)11682
Statistical analysis
  • Linagliptin 5mg + Metformin vs Linagliptin 5mg · Regression, Logistic · p = 0.0025 (The model includes treatment and continuous baseline HbA1c.) · Odds ratio (or): 2.920 · 95% CI 1.458 to 5.849
SecondaryOccurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment

The proportion of patients who achieved HbA1c below 7.0% after 24 weeks of treatment. The model includes treatment, and continuous baseline HbA1c.

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Occurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment
participantsLinagliptin 5mg + MetforminLinagliptin 5mg
Occurrence of Treat to Target Efficacy Response (HbA1c <7.0%) After 24 Weeks of Treatment8145
Statistical analysis
  • Linagliptin 5mg + Metformin vs Linagliptin 5mg · Regression, Logistic · p = 0.0008 (The model includes treatment and continuous baseline HbA1c.) · Odds ratio (or): 2.448 · 95% CI 1.453 to 4.123
SecondaryChange From Baseline in FPG by Visit Over Time

The change from baseline is the FPG over time minus the baseline FPG. Means are adjusted for treatment, continuous baseline HbA1c, continuous baseline FPG in addition to week repeated within patient, week by baseline FPG interaction and week by treatment interaction.

Time frame:
Baseline, 6, 12, 18 and 24 weeks
Reported as:
Mean · mg/dL
Change From Baseline in FPG by Visit Over Time
mg/dLLinagliptin 5mg + MetforminLinagliptin 5mg
Change to week 6-52.3 ± 3.37-31.9 ± 3.67
Change to week 12-54.1 ± 3.49-30.5 ± 3.77
Change to week 18-52.4 ± 3.20-35.4 ± 3.46
Change to week 24-47.1 ± 3.88-30.1 ± 4.16

Adverse events

Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Linagliptin 5mg + Metformin—3/159 (1.9%)39/159 (24.5%)
Linagliptin 5mg—2/157 (1.3%)51/157 (32.5%)
Most frequent serious events
Most frequent serious events
EventLinagliptin 5mg + MetforminLinagliptin 5mg
Coronary artery diseaseCardiac disorders0/1591/157
Thyroid neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1591/157
Small intestinal obstructionGastrointestinal disorders1/1590/157
Umbilical hernia, obstructiveGastrointestinal disorders1/1590/157
Menstruation irregularReproductive system and breast disorders1/1590/157
Most frequent other events
Most frequent other events
EventLinagliptin 5mg + MetforminLinagliptin 5mg
DyslipidaemiaMetabolism and nutrition disorders14/15922/157
HyperglycaemiaMetabolism and nutrition disorders5/15920/157
Urinary tract infectionInfections and infestations10/15914/157
HeadacheNervous system disorders10/1597/157
DiarrhoeaGastrointestinal disorders9/1593/157

Baseline characteristics

Patients from Treated Set (TS): All patients treated with at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Linagliptin 5mg + MetforminLinagliptin 5mgTotal
Mean49.0 ± 10.948.6 ± 11.248.8 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Linagliptin 5mg + MetforminLinagliptin 5mgTotal
Female9080170
Male6977146
Baseline HbA1c
Baseline HbA1c(percentage)Linagliptin 5mg + MetforminLinagliptin 5mgTotal
Mean9.79 ± 1.199.88 ± 1.109.83 ± 1.14
08

Study locations

82 sites
  • 1218.83.11002 Boehringer Ingelheim Investigational Site
    Phoenix, Arizona, United States
  • 1218.83.11036 Boehringer Ingelheim Investigational Site
    Little Rock, Arkansas, United States
  • 1218.83.11011 Boehringer Ingelheim Investigational Site
    Chino, California, United States
  • 1218.83.11001 Boehringer Ingelheim Investigational Site
    Huntington Beach, California, United States
  • 1218.83.11019 Boehringer Ingelheim Investigational Site
    Huntington Park, California, United States
  • 1218.83.11015 Boehringer Ingelheim Investigational Site
    Lomita, California, United States
  • 1218.83.11023 Boehringer Ingelheim Investigational Site
    Norwalk, California, United States
  • 1218.83.11014 Boehringer Ingelheim Investigational Site
    Roseville, California, United States
  • 1218.83.11031 Boehringer Ingelheim Investigational Site
    San Diego, California, United States
  • 1218.83.11022 Boehringer Ingelheim Investigational Site
    Fort Lauderdale, Florida, United States
  • 1218.83.11025 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 1218.83.11033 Boehringer Ingelheim Investigational Site
    Sanford, Florida, United States
  • 1218.83.11029 Boehringer Ingelheim Investigational Site
    Oakwood, Georgia, United States
  • 1218.83.11026 Boehringer Ingelheim Investigational Site
    Owensboro, Kentucky, United States
  • 1218.83.11008 Boehringer Ingelheim Investigational Site
    Elkton, Maryland, United States
  • 1218.83.11027 Boehringer Ingelheim Investigational Site
    Freemont, Nebraska, United States
  • 1218.83.11005 Boehringer Ingelheim Investigational Site
    Edison, New Jersey, United States
  • 1218.83.11013 Boehringer Ingelheim Investigational Site
    Jacksonville, North Carolina, United States
  • 1218.83.11028 Boehringer Ingelheim Investigational Site
    Salisbury, North Carolina, United States
  • 1218.83.11009 Boehringer Ingelheim Investigational Site
    Shelby, North Carolina, United States
  • 1218.83.11003 Boehringer Ingelheim Investigational Site
    Franklin, Ohio, United States
  • 1218.83.11024 Boehringer Ingelheim Investigational Site
    Gallipolis, Ohio, United States
  • 1218.83.11018 Boehringer Ingelheim Investigational Site
    Columbia, South Carolina, United States
  • 1218.83.11004 Boehringer Ingelheim Investigational Site
    Bristol, Tennessee, United States
  • 1218.83.11017 Boehringer Ingelheim Investigational Site
    Chattanooga, Tennessee, United States
  • 1218.83.11032 Boehringer Ingelheim Investigational Site
    Grand Prairie, Texas, United States
  • 1218.83.11030 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 1218.83.11034 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1218.83.11021 Boehringer Ingelheim Investigational Site
    Tomball, Texas, United States
  • 1218.83.12011 Boehringer Ingelheim Investigational Site
    Calgary, Alberta, Canada
  • 1218.83.12007 Boehringer Ingelheim Investigational Site
    Edmonton, Alberta, Canada
  • 1218.83.12001 Boehringer Ingelheim Investigational Site
    Red Deer, Alberta, Canada
  • 1218.83.12002 Boehringer Ingelheim Investigational Site
    Paradise, Newfoundland and Labrador, Canada
  • 1218.83.12009 Boehringer Ingelheim Investigational Site
    St. John's, Newfoundland and Labrador, Canada
  • 1218.83.12005 Boehringer Ingelheim Investigational Site
    Kitchener, Ontario, Canada
  • 1218.83.12006 Boehringer Ingelheim Investigational Site
    London, Ontario, Canada
  • 1218.83.12003 Boehringer Ingelheim Investigational Site
    Smiths Falls, Ontario, Canada
  • 1218.83.12010 Boehringer Ingelheim Investigational Site
    Sudbury, Ontario, Canada
  • 1218.83.12012 Boehringer Ingelheim Investigational Site
    Winnipeg, Ontario, Canada
  • 1218.83.91003 Boehringer Ingelheim Investigational Site
    Bangalore, India
  • 1218.83.91005 Boehringer Ingelheim Investigational Site
    Chennai, India
  • 1218.83.91001 Boehringer Ingelheim Investigational Site
    Mumbai, India
  • 1218.83.97004 Boehringer Ingelheim Investigational Site
    Haifa, Israel
  • 1218.83.97005 Boehringer Ingelheim Investigational Site
    Haifa, Israel
  • 1218.83.97007 Boehringer Ingelheim Investigational Site
    Holon, Israel
  • 1218.83.60001 Boehringer Ingelheim Investigational Site
    Kelantan, Malaysia
  • 1218.83.60002 Boehringer Ingelheim Investigational Site
    Perak, Malaysia
  • 1218.83.60003 Boehringer Ingelheim Investigational Site
    Selangor, Malaysia, Malaysia
  • 1218.83.52004 Boehringer Ingelheim Investigational Site
    Cuautla, Mexico
  • 1218.83.52001 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1218.83.52002 Boehringer Ingelheim Investigational Site
    Guadalajara, Mexico
  • 1218.83.52005 Boehringer Ingelheim Investigational Site
    Merida, Mexico
  • 1218.83.52003 Boehringer Ingelheim Investigational Site
    Tampico, Mexico
  • 1218.83.63007 Boehringer Ingelheim Investigational Site
    Cebu City, Philippines
  • 1218.83.63001 Boehringer Ingelheim Investigational Site
    Cebu, Philippines
  • 1218.83.63008 Boehringer Ingelheim Investigational Site
    Iloilo City, Philippines
  • 1218.83.63003 Boehringer Ingelheim Investigational Site
    Iloilo, Philippines
  • 1218.83.63002 Boehringer Ingelheim Investigational Site
    Marikina City, Philippines
  • 1218.83.63006 Boehringer Ingelheim Investigational Site
    Marikina City, Philippines
  • 1218.83.63004 Boehringer Ingelheim Investigational Site
    Quezon, Philippines
  • 1218.83.11037 Boehringer Ingelheim Investigational Site
    San Juan, Puerto Rico
  • 1218.83.07001 Boehringer Ingelheim Investigational Site
    Kazan, Russian Federation
  • 1218.83.07002 Boehringer Ingelheim Investigational Site
    Petrozavodsk, Russian Federation
  • 1218.83.07004 Boehringer Ingelheim Investigational Site
    Samara, Russian Federation
  • 1218.83.07006 Boehringer Ingelheim Investigational Site
    Smolensk, Russian Federation
  • 1218.83.07003 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1218.83.07007 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1218.83.07005 Boehringer Ingelheim Investigational Site
    Yaroslavl, Russian Federation
  • 1218.83.94004 Boehringer Ingelheim Investigational Site
    Dehiwela, Sri Lanka
  • 1218.83.94002 Boehringer Ingelheim Investigational Site
    Galle, Sri Lanka, Sri Lanka
  • 1218.83.94003 Boehringer Ingelheim Investigational Site
    Kandy, Sri Lanka
  • 1218.83.94001 Boehringer Ingelheim Investigational Site
    Ragama, Sri Lanka
  • 1218.83.66002 Boehringer Ingelheim Investigational Site
    Bangkok, Thailand
  • 1218.83.66003 Boehringer Ingelheim Investigational Site
    Bangkok, Thailand
  • 1218.83.66001 Boehringer Ingelheim Investigational Site
    Muang, Khonkaen, Thailand
  • 1218.83.38007 Boehringer Ingelheim Investigational Site
    Dnepropetrovsk, Ukraine
  • 1218.83.38001 Boehringer Ingelheim Investigational Site
    Ivano-Frankivsk, Ukraine
  • 1218.83.38006 Boehringer Ingelheim Investigational Site
    Kharkiv, Ukraine
  • 1218.83.38004 Boehringer Ingelheim Investigational Site
    Odessa, Ukraine
  • 1218.83.38008 Boehringer Ingelheim Investigational Site
    Vinnitsa, Ukraine
  • 1218.83.38003 Boehringer Ingelheim Investigational Site
    Vinnytsya, Ukraine
  • 1218.83.38005 Boehringer Ingelheim Investigational Site
    Vinnytsya, Ukraine
09

References and documents

Publications

  • Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgrad Med. 2016 Nov;128(8):747-754. doi: 10.1080/00325481.2016.1238280. Epub 2016 Sep 29. PubMed 27684308 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 20, 2012
Start
Jan 2012
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
May 9, 2014
Last update
May 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01512979
Responsible party
Sponsor
First posted
Jan 20, 2012
Start date
Jan 2012
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
May 9, 2014
Last update
May 20, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion